NKGen Biotech, Inc. (NKGN) Income Statement
NKGN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNKGN revenue and net income
NKGN profit margins
NKGN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NKGN quarterly EPS vs estimates
NKGen Biotech beat the analyst EPS estimate in 0 of the last 2 quarters.
NKGN income statement
| 2025 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $77,000 | $426,000 |
| Cost of revenue | — | $1.2M | $18,000 | $30,000 |
| Gross profit | — | −$1.2M | $59,000 | $396,000 |
| Research & development | $10.7M | $15.7M | $16.7M | $14.7M |
| Sales, general & admin | $16.3M | $14.1M | $7.7M | $7.6M |
| Total operating expenses | $27.0M | $29.7M | $24.4M | $22.3M |
| Operating income | −$27.0M | −$29.7M | −$24.3M | −$21.9M |
| Interest expense | $2.7M | $745,000 | $2.3M | $1.3M |
| Income before taxes | −$44.2M | −$82.9M | −$26.7M | −$23.3M |
| Income taxes | $53,000 | $7,000 | $7,000 | $5,000 |
| Net income | −$44.3M | −$83.0M | −$26.8M | −$23.3M |
| EBITDA | −$40.2M | −$81.0M | −$23.2M | −$20.7M |
| EPS (diluted) | −$0.74 | −$4.10 | $0.21 | −$0.05 |
| Gross margin | — | — | 76.6% | 93.0% |
| Operating margin | — | — | −31,618.2% | −5,131.7% |
| Net margin | — | — | −34,745.5% | −5,461.3% |
| Dec '25 | Sep '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $652,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3,000 |
| Cost of revenue | — | $326,000 | — | — | — | $326,000 | $300,000 | $300,000 | — | — | $15,000 | $0 |
| Gross profit | — | $326,000 | — | — | — | −$326,000 | −$300,000 | −$300,000 | — | — | −$15,000 | $3,000 |
| Research & development | $1.9M | $1.9M | $1.9M | $2.8M | $3.1M | $3.2M | $4.1M | $3.9M | $4.0M | $3.6M | $4.1M | $4.1M |
| Sales, general & admin | $2.8M | $3.6M | $2.8M | $4.0M | $4.4M | $4.4M | $5.3M | $3.0M | $2.6M | $3.2M | $2.2M | $1.9M |
| Total operating expenses | $4.7M | $5.4M | $4.7M | $6.8M | $7.5M | $7.6M | $9.4M | $6.9M | $6.6M | $6.8M | $6.2M | $6.0M |
| Operating income | −$4.7M | −$5.1M | −$4.7M | −$6.8M | −$7.5M | −$7.6M | −$9.4M | −$6.9M | −$6.6M | −$6.8M | −$6.3M | −$6.0M |
| Interest expense | $509,000 | $4.9M | $509,000 | $472,000 | $647,000 | $1.1M | $438,000 | $211,000 | $62,000 | $34,000 | $616,000 | $636,000 |
| Income before taxes | $15.3M | −$29.4M | $15.3M | $6.6M | −$16.1M | −$5.4M | −$33.6M | −$33.2M | −$7.8M | −$8.3M | −$6.9M | −$6.7M |
| Income taxes | — | $53,000 | — | — | $647,000 | $282,724 | $7,000 | −$89,000 | $286,778 | $403,994 | $7,000 | $179,478 |
| Net income | $15.3M | −$29.4M | $15.3M | $6.6M | −$16.1M | −$5.4M | −$33.6M | −$33.2M | −$7.8M | −$8.3M | −$6.9M | −$6.7M |
| EBITDA | $16.2M | $13.0M | $16.2M | $7.4M | −$15.1M | −$4.0M | −$32.9M | −$32.7M | −$7.5M | −$8.0M | −$5.6M | −$6.1M |
| EPS (diluted) | −$0.04 | −$0.66 | −$0.04 | $0.15 | −$0.67 | −$0.25 | −$1.54 | −$2.48 | −$0.11 | $0.02 | −$0.14 | $0.04 |
| Gross margin | — | 50.0% | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating margin | — | −782.2% | — | — | — | — | — | — | — | — | — | −199,733.3% |
| Net margin | — | −4,511.3% | — | — | — | — | — | — | — | — | — | −223,100.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NKGN's financial statements (latest annual report filed October 8, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NKGN financial results
NKGen Biotech reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $44.3 million. Diluted earnings per share came to −$0.74.
See the NKGN stock overview for the latest quote and news, or the NKGN chart for price history and technical indicators.
NKGN income statement FAQ
Does NKGen Biotech have revenue?
NKGen Biotech reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is NKGen Biotech profitable?
No. NKGen Biotech reported a net loss of $44.3 million in fiscal 2025.
How much does NKGen Biotech spend on research and development?
NKGen Biotech spent $10.7 million on research and development in fiscal 2025.
What are NKGen Biotech's earnings per share?
NKGen Biotech earned $-0.74 per diluted share in fiscal 2025, compared with $-4.10 a year earlier.
When does NKGen Biotech's fiscal year end?
NKGen Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on October 8, 2025.